Show simple item record

dc.contributor.authorMartin, Stephen A.
dc.contributor.authorBoucher, Marcy Keddy
dc.contributor.authorWright, James M.
dc.contributor.authorSaini, Vikas
dc.date2022-08-11T08:08:36.000
dc.date.accessioned2022-08-23T16:00:49Z
dc.date.available2022-08-23T16:00:49Z
dc.date.issued2014-09-14
dc.date.submitted2016-09-01
dc.identifier.citationMartin SA, Boucher M, Wright JM, Saini V. Mild hypertension in people at low risk. BMJ. 2014 Sep 14;349:g5432. doi: 10.1136/bmj.g5432. PubMed PMID: 25224509.
dc.identifier.issn1756-1833
dc.identifier.doi10.1136/bmj.g5432
dc.identifier.pmid25224509
dc.identifier.urihttp://hdl.handle.net/20.500.14038/30973
dc.description.abstractAntihypertensive drugs have an important role in the treatment of malignant hypertension, secondary prevention of cardiovascular disease, and primary prevention for people at high risk: those with moderate to severe hypertension (≥160/100 mm Hg), diabetes, or chronic kidney disease. Debate continues, however, about the level at which treatment should begin and the appropriate targets for treatment. The greatest uncertainty surrounds mild hypertension (140-159/90-99 mm Hg), which accounts for over 60% of those with hypertension or 22% of the global adult population. Evidence suggests no net benefit from drug treatment of mild hypertension in people without the higher risks of diabetes or chronic kidney disease. Nevertheless, most people with mild hypertension are treated with drugs. In this article, we examine the overdiagnosis and overtreatment of mild hypertension.
dc.language.isoen_US
dc.publisherBritish Medical Association
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25224509&dopt=Abstract">Link to article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1136/bmj.g5432
dc.subjectCardiovascular Diseases
dc.subjectCommunity Health and Preventive Medicine
dc.subjectDiagnosis
dc.subjectFamily Medicine
dc.subjectPreventive Medicine
dc.subjectPrimary Care
dc.subjectTherapeutics
dc.titleMild hypertension in people at low risk
dc.typeJournal Article
dc.source.journaltitleBMJ (Clinical research ed.)
dc.source.volume349
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/fmch_articles/317
dc.identifier.contextkey9064128
html.description.abstract<p>Antihypertensive drugs have an important role in the treatment of malignant hypertension, secondary prevention of cardiovascular disease, and primary prevention for people at high risk: those with moderate to severe hypertension (≥160/100 mm Hg), diabetes, or chronic kidney disease. Debate continues, however, about the level at which treatment should begin and the appropriate targets for treatment. The greatest uncertainty surrounds mild hypertension (140-159/90-99 mm Hg), which accounts for over 60% of those with hypertension or 22% of the global adult population. Evidence suggests no net benefit from drug treatment of mild hypertension in people without the higher risks of diabetes or chronic kidney disease. Nevertheless, most people with mild hypertension are treated with drugs. In this article, we examine the overdiagnosis and overtreatment of mild hypertension.</p>
dc.identifier.submissionpathfmch_articles/317
dc.contributor.departmentDepartment of Family Medicine and Community Health
dc.source.pagesg5432


This item appears in the following Collection(s)

Show simple item record